$1,351.12−$31.63 (−2.29%) on the dayAs of the close; data may be delayed.
LLY price, last 12 months
$1,444$851.21$1,351
Daily closes over the last 260 trading sessions: +46.2%. Highest close $1,443.50 on , lowest $851.21 on . Market data may be delayed.
Key stats
Previous close
$1,382.75
Open
$1,369.38
Day range
$1,341.46 – $1,382.00
52-week range
$850.51 – $1,475.25
Volume
3.2M
Avg volume (20 days)
3.1M
Market cap
$1.3T
Performance
1W−6.6%
1M+3.2%
3M+8.2%
6M+26.7%
YTD+25.5%
1Y+28.5%
vs S&P 500, 1Y+23.7 pts
Technicals and fundamentals
About Eli Lilly & Co.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Chart LLY with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full LLY chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.
Technicals
RSI (14)49.8mid-range
vs 50-day average+6.5%
vs 200-day average+20.7%price above both averages
MACDBelow signal
Daily range (ATR)3.2%average true range, % of price
52w low $850.5152w high $1,475.25
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)43.71.93x Manufacturing median (22.6)
P/E (forward)26.6
PEG1.28
Price / sales13.95
Price / book29.90
EV / EBITDA—
P/E since Jun 135.5 – 46.6
Company figures as of Nov 19, 2026.
Analysts
ConsensusBuy1.7 on 1 (strong buy) to 5 (strong sell)
Analysts29
Average target$1,468.57+8.9% from today
Price targets are opinions and tend to lean optimistic.
Earnings
Next results, expectedaround Feb 3, 2027 (in 75 days)A year after its Feb 4, 2026 results release; the last came Oct 29, 2026. An estimate from its SEC filings, not a date the company announced.
Dividends & splits
Paid, last 12 months$6.92quarterly
Yield at today's price0.51%
Change vs the year before+15.3%
Payout ratio22%share of earnings paid out
Nov 13$1.73Aug 14$1.73May 15$1.73Feb 13$1.73Nov 14$1.50Aug 15$1.50
Seasonality
-0.9
J
+4.8
F
+1.1
M
+5.6
A
+4.2
M
+7.5
J
-4.4
J
+6.5
A
+0.1
S
+9.1
O
+5.4
N
+1.1
D
Average return in each calendar month, Oct 31, 2021 to Oct 31, 2026. 6 years is 6 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
−3
+1
−13
+2
+18
+9
−4
+1
+0
+23
+32%
2025
+5
+14
−10
+9
−18
+6
−5
−1
+4
+13
+25
−0
+39%
2024
+11
+17
+3
+0
+5
+10
−11
+19
−8
−6
−4
−3
+32%
2023
−6
−10
+10
+15
+8
+9
−3
+22
−3
+3
+7
−1
+59%
2022
−11
+2
+15
+2
+7
+3
+2
−9
+7
+12
+2
−1
+32%
2021
+10
−3
+11
+20%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q3 FY2026, ended Sep 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
Strong financial performance with 39% revenue growth in Q3, excellent sales for Mounjaro and Zepbound, upcoming retatrutide regulatory filing in Q1 2027, and potential label expansions. Projected 10.91% stock gain by end of 2027.
Company raised 2026 sales guidance to $91-92 billion (from $85-87 billion) driven by 49% increase in Zepbound sales. Strong market leadership in weight-loss drugs, diversified pipeline with promising assets like retatrutide and Kisunla, and ability to maintain pricing power despite competition.
Exceptional growth trajectory with 44.7% revenue increase, dominant position in high-demand GLP-1 market, strong net margins (31.7%), and promising pipeline including Retatrutide and lipoprotein(a) therapeutic. Premium valuation justified by sustained growth potential, though concentrated revenue dependency on two drugs presents risk.